REPL
Another analyst, another gut punch
Replimune Group is having one of those weeks where the bad news keeps showing up like an uninvited group chat. According to the latest analyst note, Cantor Fitzgerald turned neutral on the stock and set a $0 price target on April 13, 2026.
That’s not exactly a vote of confidence. It’s the kind of call that tells you Wall Street is treating the next 12 months with the emotional energy of a canceled vacation.
Why investors should care
Analyst calls don’t change a company’s science, but they do change the mood music around a stock. And for Replimune, the mood is already sour thanks to the FDA setbacks from the same day.
When a name gets:
- a fresh downgrade,
- a zero-dollar target,
- and ongoing regulatory uncertainty,
…you’re not looking at a gentle recalibration. You’re looking at a market that’s basically asking, “show me the data, and maybe a miracle too.”
The bigger picture
This isn’t just about one analyst being grumpy. It’s about sentiment collapsing around a biotech story that needs everything to go right.
If the regulatory path stays messy, Wall Street may keep compressing its expectations faster than management can rebuild them. Big picture: in biotech, your science can still matter a ton — but right now, Replimune’s stock is trading like the bears have the better script.